BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today
that it will report results from a Phase I pharmacologic trial of
sapacitabine (CYC682), a novel orally-available nucleoside analog,
in patients with advanced leukemias or myelodysplastic syndromes
(MDS), at the American Society of Clinical Oncology's (ASCO) Annual
Meeting at McCormick Place in Chicago. Details of the presentation
are as follows:
Abstract # 7063, Poster # M8
Phase I study of sapacitabine, an oral nucleoside analogue, in
patients with advanced leukemias or myelodysplastic syndromes.
General Poster Session: Saturday, June 2, 2007, 8:00 AM - 12:00
pm Central Time
Presenters: Dr. Hagop Kantarjian, Professor of Medicine and
Chairman, Department of Leukemia and Dr. William Plunkett,
Professor and Chief, Section of Molecular and Cellular Oncology,
Department of Experimental Therapeutics both at the University of
Texas M.D. Anderson Cancer Center (UTMDACC) in Houston, Texas.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the
discovery, development and commercialization of novel,
mechanism-targeted drugs to treat human cancers and other serious
disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine
(CYC682), an orally-available, cell cycle modulating nucleoside
analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and
seliciclib (CYC202), an orally-available CDK (cyclin dependent
kinase) inhibitor, for the treatment of lung cancer. Sapacitabine
is also in Phase I trials in patients with hematologic
malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2
inhibitor, is at the IND stage. Several additional programs are at
an earlier stage.
Please visit
http://www.cyclacel.com/cyc/investors/news/pressreleases for
additional information.
Note: The Cyclacel
'"/>
Page: 1 2 3 Related medicine technology :1.
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies2.
Cyclacel Pharmaceuticals to Present Preclinical Data on
Sapacitabine and Seliciclib at AACR3.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine4.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis5.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone6.
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference7.
Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference8.
EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference9.
Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings10.
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea11.
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)